Mogamulizumab
- Generic Name
- Mogamulizumab
- Brand Names
- Poteligeo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1159266-37-1
- Unique Ingredient Identifier
- YI437801BE
- Background
Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect th...
- Indication
Mogamulizumab is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
- Associated Conditions
- Refractory Mycosis Fungoides and Sezary Syndrome, Relapsed Mycosis Fungoides/Sezary Syndrome
- Associated Therapies
- -
KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02867007
Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-02-09
- Last Posted Date
- 2018-11-30
- Lead Sponsor
- Kyowa Kirin, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT02358473
- Locations
- 🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸John Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸Horizon Oncology, Lafayette, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.